S&P 500   3,002.83 (+0.56%)
DOW   26,792.96 (+0.09%)
QQQ   193.18 (+0.78%)
AAPL   240.85 (+1.88%)
FB   189.26 (+1.83%)
GOOGL   1,244.50 (+0.01%)
AMZN   1,781.54 (+1.37%)
CGC   20.40 (+0.94%)
NVDA   195.79 (+2.78%)
MU   44.97 (+3.45%)
GE   8.84 (-1.34%)
TSLA   252.16 (-1.86%)
T   38.26 (-0.55%)
F   9.03 (-2.80%)
BAC   30.98 (+2.08%)
GILD   65.22 (+0.48%)
S&P 500   3,002.83 (+0.56%)
DOW   26,792.96 (+0.09%)
QQQ   193.18 (+0.78%)
AAPL   240.85 (+1.88%)
FB   189.26 (+1.83%)
GOOGL   1,244.50 (+0.01%)
AMZN   1,781.54 (+1.37%)
CGC   20.40 (+0.94%)
NVDA   195.79 (+2.78%)
MU   44.97 (+3.45%)
GE   8.84 (-1.34%)
TSLA   252.16 (-1.86%)
T   38.26 (-0.55%)
F   9.03 (-2.80%)
BAC   30.98 (+2.08%)
GILD   65.22 (+0.48%)
Log in

Regeneron Pharmaceuticals Stock Price, News & Analysis (NASDAQ:REGN)

$296.25
-3.94 (-1.31 %)
(As of 10/21/2019 01:47 PM ET)
Today's Range
$294.86
Now: $296.25
$301.97
50-Day Range
$273.46
MA: $288.14
$308.15
52-Week Range
$271.37
Now: $296.25
$442.00
Volume265,272 shs
Average Volume785,658 shs
Market Capitalization$32.54 billion
P/E Ratio14.96
Dividend YieldN/A
Beta1.14
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.71 billion
Cash Flow$21.82 per share
Book Value$80.34 per share

Profitability

Net Income$2.44 billion

Miscellaneous

Employees7,400
Market Cap$32.54 billion
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, beating the Zacks' consensus estimate of $4.60 by $0.69. The biopharmaceutical company had revenue of $1.93 billion for the quarter, compared to analysts' expectations of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The firm's revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.45 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Regeneron Pharmaceuticals.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for REGN?

18 equities research analysts have issued twelve-month price objectives for Regeneron Pharmaceuticals' stock. Their predictions range from $320.00 to $480.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $385.38 in the next year. This suggests a possible upside of 30.2% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Regeneron’s fourth-quarter results were impressive as the company comfortably beat on both the top and the bottom line. Regeneron’s growth driver, Eylea continues to drive sales, and label expansion of the drug into additional indications has further boosted growth. Dupixent too has boosted performance. The company is working to expand Dupixent’s label further in several other indications. This should diversify the company’s revenue base and reduce dependence on Eylea. In September 2018, the FDA approved its immuno-oncology therapy, Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. New drug approvals boost growth prospects of the company. Shares have outperformed the industry in the past six months. However, the company is highly dependent on Eylea for growth." (2/8/2019)
  • 2. Cantor Fitzgerald analysts commented, "We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares." (2/6/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "REGN today reported in-line 3Q product sales (total rev +$21M; 1%) and a bottom-line beat (+$0.74; 14%) while tightening and lowering OpEx/tax guidance. The 3Q print/call was rather uneventful albeit high on details; Eylea was generally in line with expectations (+7% YoY), and Dupixent/Praluent/Kevzara numbers were known following SNY’s print last Wednesday. With many (not all) 4Q18 clinical/regulatory catalysts in the rear view mirror, we expect investors to focus on ongoing product launches and the robustness of the Eylea franchise. Maintain Neutral." (11/7/2018)

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

News stories about REGN stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Regeneron Pharmaceuticals.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Allergan (AGN) and Broadcom (AVGO).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.38%), Hexavest Inc. (0.08%), DNB Asset Management AS (0.05%), Envestnet Asset Management Inc. (0.04%), Strs Ohio (0.04%) and Assenagon Asset Management S.A. (0.03%). Company insiders that own Regeneron Pharmaceuticals stock include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Bowling Portfolio Management LLC, Gateway Investment Advisers LLC, Strs Ohio, Robeco Institutional Asset Management B.V., Envestnet Asset Management Inc. and Crossmark Global Holdings Inc.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, Joseph L Goldstein, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., DNB Asset Management AS, Pacer Advisors Inc., Oakbrook Investments LLC, YHB Investment Advisors Inc., CIBC Private Wealth Group LLC, State of Alaska Department of Revenue and Hexavest Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $295.89.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $32.50 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,269 (Vote Outperform)
Underperform Votes:  1,088 (Vote Underperform)
Total Votes:  2,357
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: Stocks Increasing Dividends

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel